Systematic review / meta-analysis / 2016
Niacin therapy is associated with a moderately increased risk of new-onset diabetes in randomized controlled trials.
A meta-analysis of 11 randomized controlled trials evaluated the link between niacin therapy and new-onset diabetes in 26,340 non-diabetic participants over a weighted mean follow-up of 3.6 years. In total, 1,371 participants developed diabetes (725 of 13,121 assigned to niacin vs 646 of 13,219 controls). Niacin was associated with a significantly higher risk of new-onset diabetes (RR 1.34, 95% CI 1.21 to 1.49; I2 = 0.0%), equating to one extra diabetes case per 43 participants treated for 5 years. Results remained consistent regardless of background statin therapy (p = 0.88) or combination with laropiprant (p = 0.52).
- Study type
- Meta-analysis of randomized controlled trials
- Who was studied
- 26,340 non-diabetic participants across 11 trials
- What was measured
- New-onset diabetes
THE PAPER
Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials.
Goldie C, Taylor AJ, Nguyen P, McCoy C, Zhao XQ, Preiss D. Heart, 2016.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.